The effect of propolis in diabetic patients

INTERVENTION: Intervention 1: Propolis, capsule 500mg, oral, twice daily, 3 month. Intervention 2: Soya, capsules 500mg, oral, twice daily, 3 month. Placebo Propolis, capsule 500mg, oral, twice daily, 3 month Soya, capsules 500mg, oral, twice daily, 3 month Treatment ‐ Drugs CONDITION: Non‐insulin‐dependent diabetes mellitus Type 2 diabetes. ; Non‐insulin‐dependent diabetes mellitus SECONDARY OUTCOME: Sensivity. Timepoint: in the begining, monthly and in the end of intervention. Method of measurement: patient complain, physical examination. INCLUSION CRITERIA: INCLUSION CRITERIA: age 25‐80 years; Hemoglobin A1c (HbA1c) Test between 5.9‐8%; Fast blood sugar between 126‐200 mg/dl; patients were diagnosed less than 10 years; patients should only use oral hypoglycemic agents Exclusion criteria: Pregnancy and lactation; Insulin dependent diabetes; sensivity to honey or bee products; Severe renal or hepatitis failure PRIMARY OUTCOME: 2 hours post prandial glucose. Timepoint: in the beginning and in the End of Intervention. Method of measurement: mg/dl by using specific serum kit. ALANIN AMINOTRANSFERASE. Timepoint: in the beginning and in the End of Intervention. Method of measurement: mg/dl by using specific serum kit. ALKALIN PHOSPHATASE. Timepoint: in the beginning and in the End of Intervention. Method of measurement: mg/dl by using specific serum kit. ASPATRTATE AMINOTRANSFERASE. Timepoint: in the beginning and in the End of Intervention. Method of measurement: mg/dl by using specific serum kit. Blood pressure. Timepoint: in the beginning and in the End of Intervention. Method of measurement: mmHg by using indicator. BLOOD UREA NITROGEN. Timepoint: in the beginning and in the End of Intervention. Method of measurement: mg/dl by using specific serum kit. Body Mass Index (BMI). Timepoint: in the beginning and in the End of Intervention. Method of measurement: kg/m2 by measuring height and weight and use of scale. Cholestrol. Timepoint: in the beginning and in the End of Intervention. Method of measurement: mg/dl by using specific serum kit. Creatinine. Timepoint: in the beginning and in the End of Intervention. Method of measurement: mg/dl by using specific serum kit. Estimated Glomelural Filtration Rate. Timepoint: in the beginning and in the End of Intervention. Method of measurement: mg/min/1.73m2 by using formula. Fasting Blood Serum. Timepoint: in the beginning, monthly and in the End of Intervention. Method of measurement: mg/dl with using specific serum kit. HbA1C. Timepoint: in the beginning and in the End of Intervention. Method of measurement: % by using specific serum kit. High Density Lipoprotein (HDL). Timepoint: in the beginning and in the End of Intervention. Method of measurement: mg/dl by using specific serum kit. High sensitity C‐ reactive protein. Timepoint: in the beginning and in the End of Intervention. Method of measurement: ng/ml by using specific serum kit. Homeostasis model assessment of ß‐cell function. Timepoint: in the beginning and in the End of Intervention. Method of measurement: %by using formula. Homestasis model assessment Insulin resistance. Timepoint: in the beginning and in the End of Intervention. Method of measurement: %by using formula. IL1‐B. Timepoint: in the beginning and in the End of Intervention. Method of measurement: Pg/ml by using specific serum kit. IL6. Timepoint: in the beginning and in the End of Intervention. Method of measurement: Pg/ml by using specific serum kit. Low Density Lipoprotein (LDL). Timepoint: in the beginning and in the End of Intervention. Method of measurement: mg/dl by using specific serum kit. Serum Insulin. Timepoint: in the beginning and in the End of Intervention. Method of measurement: IU/ml by using specific serum kit. Triglyceride. Timepoint: in the beginning and in the End of Intervention. Method of measurement: mg/dl by using specific serum kit. Tumor Necrosis Factor a. Timepoint: in the beginning and in the End of Intervention. Method of measurement: Pg/ml by using specific serum kit. URIC ACID. Timepoint: in the beginning and in the End of Intervention. Method of measurement: mg/dl by using specific serum kit. Very Low Density Lipoprotein (VLDL). Timepoint: in the beginning and in the End of Intervention. Method of measurement: mg/dl by using specific serum kit.